BeiGene
Presence
BeiGene is one of the...
BeiGene is a company listed under the stock ticker 6160 (HK).
BeiGene has a direct presence in 2 countries.
They are in:
- Biotechnology67%
- Pharmaceuticals33%
Executives
View the org chart displaying its 69 main executives
Most searched biographies at BeiGene
- John Oyler, Chairman and Chief Executive Officer
- Corsee Sanders, Director
- Ranjeev Krishana, Director
Popular executive movements at BeiGene
- Thomas Malley, Non-Executive Independent Director, has left the company (posted on January 24 2024).
- Olivier Brandicour has joined the company as Director (posted on January 24 2024).
Create your alert
to follow the executive moves at BeiGene.
Pharmaceuticals
BeiGene has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by BeiGene
- Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFil
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present at Upcoming Investor Conferences – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- View more press releases Close
Social media about BeiGene
- BeiGene on Wikipedia, Google News & Yahoo Finance
- BeiGene on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including John Oyler 
